These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 24690215)

  • 21. Clinical trial designs for predictive biomarker validation: one size does not fit all.
    Mandrekar SJ; Sargent DJ
    J Biopharm Stat; 2009; 19(3):530-42. PubMed ID: 19384694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Designing a study to evaluate the benefit of a biomarker for selecting patient treatment.
    Janes H; Brown MD; Pepe MS
    Stat Med; 2015 Nov; 34(27):3503-15. PubMed ID: 26112650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. On Enrichment Strategies for Biomarker Stratified Clinical Trials.
    Wang X; Zhou J; Wang T; George SL
    J Biopharm Stat; 2018; 28(2):292-308. PubMed ID: 28933670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies.
    Barry WT; Perou CM; Marcom PK; Carey LA; Ibrahim JG
    J Biopharm Stat; 2015; 25(1):66-88. PubMed ID: 24836519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit.
    Royston P; Barthel FM; Parmar MK; Choodari-Oskooei B; Isham V
    Trials; 2011 Mar; 12():81. PubMed ID: 21418571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints.
    Mehta C; Schäfer H; Daniel H; Irle S
    Stat Med; 2014 Nov; 33(26):4515-31. PubMed ID: 25130879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhancing pediatric clinical trial feasibility through the use of Bayesian statistics.
    Huff RA; Maca JD; Puri M; Seltzer EW
    Pediatr Res; 2017 Nov; 82(5):814-821. PubMed ID: 28700566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using re-randomization to increase the recruitment rate in clinical trials - an assessment of three clinical areas.
    Kahan BC
    Trials; 2016 Dec; 17(1):595. PubMed ID: 27964743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate cancer chemoprevention: Strategies for designing efficient clinical trials.
    Lieberman R
    Urology; 2001 Apr; 57(4 Suppl 1):224-9. PubMed ID: 11295633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.
    Brookes ST; Whitley E; Peters TJ; Mulheran PA; Egger M; Davey Smith G
    Health Technol Assess; 2001; 5(33):1-56. PubMed ID: 11701102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal sequential enrichment designs for phase II clinical trials.
    Zang Y; Yuan Y
    Stat Med; 2017 Jan; 36(1):54-66. PubMed ID: 27640874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicenter trials using ¹⁸F-fluorodeoxyglucose (FDG) PET to predict chemotherapy response: effects of differential measurement error and bias on power calculations for unselected and enrichment designs.
    Kurland BF; Doot RK; Linden HM; Mankoff DA; Kinahan PE
    Clin Trials; 2013; 10(6):886-95. PubMed ID: 24169628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating many treatments and biomarkers in oncology: a new design.
    Kaplan R; Maughan T; Crook A; Fisher D; Wilson R; Brown L; Parmar M
    J Clin Oncol; 2013 Dec; 31(36):4562-8. PubMed ID: 24248692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A simulation study of outcome adaptive randomization in multi-arm clinical trials.
    Wathen JK; Thall PF
    Clin Trials; 2017 Oct; 14(5):432-440. PubMed ID: 28982263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Bayesian dose-finding trial with adaptive dose expansion to flexibly assess efficacy and safety of an investigational drug.
    Berry SM; Spinelli W; Littman GS; Liang JZ; Fardipour P; Berry DA; Lewis RJ; Krams M
    Clin Trials; 2010 Apr; 7(2):121-35. PubMed ID: 20338905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized phase II trial designs with biomarkers.
    Freidlin B; McShane LM; Polley MY; Korn EL
    J Clin Oncol; 2012 Sep; 30(26):3304-9. PubMed ID: 22869885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The net effect of alternative allocation ratios on recruitment time and trial cost.
    Vozdolska R; Sano M; Aisen P; Edland SD
    Clin Trials; 2009 Apr; 6(2):126-32. PubMed ID: 19342464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimizing Aggregated N-Of-1 Trial Designs for Predictive Biomarker Validation: Statistical Methods and Theoretical Findings.
    Hendrickson RC; Thomas RG; Schork NJ; Raskind MA
    Front Digit Health; 2020; 2():13. PubMed ID: 34713026
    [No Abstract]   [Full Text] [Related]  

  • 40. Marker Sequential Test (MaST) design.
    Freidlin B; Korn EL; Gray R
    Clin Trials; 2014 Feb; 11(1):19-27. PubMed ID: 24085774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.